Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

64.26EUR
15 Aug 2018
Change (% chg)

€-0.92 (-1.41%)
Prev Close
€65.18
Open
€65.30
Day's High
€65.70
Day's Low
€64.10
Volume
973,498
Avg. Vol
1,308,784
52-wk High
€72.76
52-wk Low
€58.96

Select another date:

Tue, Jul 31 2018

UPDATE 3-Akorn row overshadows Fresenius' generics guidance

* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)

Fresenius nudges up Kabi earnings guidance

BERLIN, July 31 Fresenius SE nudged up its earnings guidance for its Kabi generics unit on Tuesday as it posted a 3 percent rise in adjusted group net profit in the second quarter.

Fresenius transfers inpatient rehabilitation business to Vamed unit

FRANKFURT, June 6 German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses.

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius Q1 net income slips 2 pct on strong euro

BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

UPDATE 2-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

Fresenius alleges "blatant fraud" at abandoned target Akorn

WILMINGTON, Del., May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.

Select another date: